Plasma Fractionation Market Size Worth $28.2 billion by 2027 - KBV Research

The Immunoglobulins market dominated the Global Plasma Fractionation Market by Product in 2020, growing at a CAGR of 9.4 % during the forecast period. The Albumin market is experiencing a CAGR of 9.2% during (2021 - 2027). Additionally, The Coagulation factor VIII market is expected to witness highest CAGR of 11.2% during (2021 - 2027).

The Private Sector market dominated the Global Plasma Fractionation Market by Sector in 2020, and would continue to be a dominant market till 2027. The Public Sector market is expected to witness a CAGR of 10.4% during (2021 - 2027).

In North America, the US procured the maximum share of the plasma fractional market in 2020. This is owing to the increasing geriatric population and related diseases. The Alzheimer’s Association noted that approximately 5.8 million individuals in the United State are suffering from Alzheimer’s diseases in 2018. This disease is the sixth major cause of death in the United States and is more prevalent among people more than 65 years of age, as around 5.6 million patients fall in this age group. With the baby-boom generation arriving approximately 65 years of age, this number would reach 14 million, deteriorating the situation during the forecast period. In addition, key makers are aiming to expand their geographical presence in developing countries of APAC to exploiter the untapped opportunities. This, in turn, would support the growth of the regional plasma fractionation market.

Full Report: https://www.kbvresearch.com/plasma-fractionation-market/

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Emergent BioSolutions, Inc., CSL Limited, Grifols S.A., Octapharma AG, Takeda Pharmaceutical Company Limited, Kedrion S.p.A, LFB S.A, Biotest AG (Tiancheng International Investment Limited), Sanquin Blood Supply Foundation, and Bio Products Laboratory Limited.

Global Plasma Fractionation Market Segmentation

By Product

• Immunoglobulins


• Albumin


• Coagulation factor VIII


• Coagulation factor IX

By Sector

• Private Sector


• Public Sector

By Geography

North America

• US


• Canada


• Mexico


• Rest of North America

Europe

• Germany


• UK


• France


• Russia


• Spain


• Italy


• Rest of Europe

Asia Pacific

• China


• Japan


• India


• South Korea


• Singapore


• Malaysia


• Rest of Asia Pacific

LAMEA

• Brazil


• Argentina


• UAE


• Saudi Arabia


• South Africa


• Nigeria


• Rest of LAMEA

Companies Profiled

• Emergent BioSolutions, Inc.


• CSL Limited


• Grifols S.A.


• Octapharma AG


• Takeda Pharmaceutical Company Limited


• Kedrion S.p.A


• LFB S.A


• Biotest AG (Tiancheng International Investment Limited)


• Sanquin Blood Supply Foundation


• Bio Products Laboratory Limited